NAD+ is closely connected to mitochondrial function and energy metabolism, which makes it a major area of interest in performance and metabolic research. Human studies on NAD+ precursors such as NMN have explored whether supporting NAD+ availability can influence exercise-related and metabolic markers.

In a randomized, double-blind study of 48 recreational runners, NMN supplementation was combined with exercise training over six weeks. The study reported greater improvements in oxygen uptake and ventilatory-threshold-related power in the medium- and high-dose NMN groups compared with placebo, suggesting potential support for aerobic capacity during training.

Another randomized, multicenter, double-blind, placebo-controlled trial in 80 healthy middle-aged adults found that NMN significantly increased blood NAD concentrations after 30 and 60 days, with no safety concerns identified in the monitored clinical and laboratory measures.

These findings position NAD+ support as a promising research area for cellular energy, physical performance, and metabolic resilience. Larger and longer studies will help clarify the full potential, but current human data is encouraging.

References:
Liao et al., Journal of the International Society of Sports Nutrition, 2021.
Yi et al., GeroScience, 2023.

Because NAD+ itself is central to cellular energy and maintenance, researchers have studied NAD+ precursors as a way to support NAD+ availability. Nicotinamide riboside, or NR, is one of the most studied precursors in human clinical research.

In a randomized, double-blind, placebo-controlled crossover trial published in Nature Communications, researchers studied NR supplementation in healthy middle-aged and older adults. The study found that chronic NR supplementation was well tolerated and effectively stimulated NAD+ metabolism in this population.

The researchers also noted that future trials should further examine potential cardiovascular-related outcomes such as blood pressure and arterial stiffness. These findings make NAD+ precursor research especially interesting for healthy aging, as the goal is not stimulation but support for the body’s own cellular energy and maintenance systems.

Overall, NAD+ precursor research supports the idea that maintaining NAD+ metabolism may be an important part of long-term cellular wellness.

Reference:
Martens et al., Nature Communications, 2018.

Nicotinamide adenine dinucleotide, better known as NAD+, is one of the body’s most important cellular coenzymes. It plays a central role in redox reactions, helping cells convert nutrients into usable energy. NAD+ is also involved in the activity of enzymes such as sirtuins and PARPs, which are connected to cellular maintenance, stress response, and DNA repair pathways.

Research interest in NAD+ has grown because NAD+ availability appears to decline with age, making NAD+ support an important area of healthy-aging and cellular-performance research. A PRISMA-guided systematic review published in 2026 noted that NAD+-boosting strategies include lifestyle interventions and NAD+ precursors such as nicotinamide riboside and nicotinamide mononucleotide.

From a wellness perspective, NAD+ is compelling because it sits at the intersection of energy metabolism and cellular resilience. While research is still developing, NAD+ biology provides a strong foundation for products focused on cellular vitality, metabolic efficiency, and healthy aging support.

References:
NAD+ metabolism and aging review.
PRISMA-guided NAD+ supplementation review.

Beyond appetite and lipid metabolism, OEA is also being studied for its broader role in metabolic resilience. Researchers have explored its effects on glycemic markers, insulin sensitivity, oxidative stress, and antioxidant status, making it a notable compound in metabolic health research.

In a double-blind randomized clinical trial involving prediabetic subjects, 125 mg of OEA daily for 8 weeks significantly reduced blood sugar, insulin, insulin resistance, HbA1c, and CRP compared with baseline, while the placebo group did not show significant changes in those biochemical factors.

Another randomized controlled trial in subjects with NAFLD studied 250 mg/day OEA alongside a calorie-restricted diet for 12 weeks. The study reported improvements in antioxidant-related markers, including increased total antioxidant capacity and superoxide dismutase, plus reduced malondialdehyde and oxidized LDL compared with placebo. Inflammatory markers did not significantly change in that study, so the strongest findings were related to oxidative stress and antioxidant balance.

Overall, OEA appears to be a promising research-backed compound for supporting metabolic signaling, oxidative stress balance, and healthier biomarker patterns. The evidence is encouraging, while longer and larger human trials would help clarify its full potential.

References:
Pouryousefi et al., Diabetology & Metabolic Syndrome, 2022.
Tutunchi et al., Frontiers in Pharmacology, 2023.

OEA has gained attention for its role in lipid metabolism, especially because of its interaction with PPAR-α, a receptor that helps regulate genes involved in fatty-acid handling and energy balance. This mechanism positions OEA as a compound of interest for supporting metabolic health and triglyceride regulation.

In a randomized, double-blind, placebo-controlled trial published in BMC Endocrine Disorders, subjects received OEA for 8 weeks. The study reported a significant reduction in triglyceride concentration in the OEA group, while the placebo group did not show a significant change. After adjustment for baseline and demographic factors, the between-group triglyceride difference remained significant.

A 2025 systematic review and meta-analysis of randomized controlled trials also found that OEA intake was associated with significant decreases in body weight, waist circumference, fat mass, body-fat percentage, fasting blood glucose, insulin, HOMA-IR, and triglycerides, although some outcomes showed heterogeneity and should be interpreted carefully.

Taken together, the research suggests that OEA may support key markers of metabolic function, especially when used alongside sensible nutrition and lifestyle practices.

References:
Ostadrahimi et al., BMC Endocrine Disorders, 2024.
Bahari et al., Frontiers in Nutrition, 2025.

Oleoylethanolamide, commonly known as OEA, is a naturally occurring lipid messenger produced in the small intestine in response to dietary fat intake. Research has identified OEA as an important satiety-signaling compound, helping the body communicate that enough food has been consumed. Unlike stimulant-based appetite approaches, OEA works through a biological pathway tied to lipid sensing and energy balance.

A key Nature study found that OEA activates PPAR-α, a nuclear receptor involved in lipid metabolism. In the study, OEA supported satiety and reduced body-weight gain in wild-type subjects, while these effects were not observed in PPAR-α-deficient subjects, suggesting that PPAR-α is central to OEA’s mechanism.

This makes OEA especially interesting from a nutritional research perspective. Rather than forcing energy restriction, OEA appears to support the body’s natural meal-to-meal signaling system. For individuals interested in appetite awareness, metabolic efficiency, and healthier eating patterns, OEA represents a promising compound with a strong mechanistic foundation.

References:
Fu et al., Nature, 2003.
Gaetani et al., Journal of Neuroscience, 2010.